European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
REYKJAVIK, Iceland and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and…
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced…
FEMSA completa la desinversión de sus operaciones de equipos de refrigeración y de servicio de alimentos a Mill Point Capital
MONTERREY, México, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA” o la “Compañía”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) anunció hoy que ha completado exitosamente la…
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
PHILADELPHIA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced…
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious…
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug…
AMG Reports Financial and Operating Results for the Third Quarter and Nine Months Ended September 30, 2024
Company reports EPS of $3.78, Economic EPS of $4.82 in the third quarter of 2024 Net income (controlling interest) of $124 million, Economic Net Income (controlling interest) of $153 millionEconomic…
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
BOSTON and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of small molecule precision medicines for…
FEMSA completes divestiture of its refrigeration and foodservice equipment operations to Mill Point Capital
MONTERREY, Mexico, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA” or the “Company”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) announced today the successful closing of its…
Form 8.3 – MUSICMAGPIE PLC
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a)…